Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Heron Therapeutics (HRTX) NASDAQ

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 505,520
  • Shares Outstanding, K 39,190
  • Annual Sales, $ 0 K
  • Annual Income, $ -97,590 K
  • 36-Month Beta 1.66
  • Price/Sales N/A
  • Price/Book 28.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.21 +4.83%
on 01/12/17
14.50 -11.72%
on 12/19/16
-1.30 (-9.22%)
since 12/16/16
3-Month
12.21 +4.83%
on 01/12/17
20.85 -38.61%
on 11/16/16
-2.60 (-16.88%)
since 10/18/16
52-Week
12.21 +4.83%
on 01/12/17
25.46 -49.73%
on 04/19/16
-9.91 (-43.64%)
since 01/15/16

Most Recent Stories

More News
Heron Announces Submission of CINVANTI(TM) NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)

Heron Therapeutics, Inc. (NASDAQ:HRTX), a commercial-stage biotechnology company focused on developing novel best-in-class treatment solutions to address some of the biggest unmet patient...

Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in Abdominoplasty

--- Results confirm broad utility of HTX-011 with successful use across wide range of surgeries, from small to very large incisions -

Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical Studies

--- Conference call and webcast at 8:30 a.m. ET on January 5, 2017 -

Susan G. Komen(R) Joins Forces With Heron Therapeutics to Raise Awareness of the Supportive Care Needs of Patients With Breast Cancer

Susan G. Komen and Heron Therapeutics, Inc. today announced that the two organizations have joined forces to encourage supporters to take action in the fight against breast...

Heron Therapeutics Reports Financial Results for the Three and Nine Months Ended September 30, 2016 and Recent Corporate Progress

Heron Therapeutics, Inc. (NASDAQ:HRTX) (the Company or Heron), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major...

InvestorsObserver releases covered-call reports for Inovio Pharmaceuticals, Varian Medical Systems, Heron Therapeutics, Chipotle Mexican Grill and Wynn Resorts

InvestorsObserver issues critical PriceWatch Alerts for CMG, HRTX, INO, VAR, and WYNN.

Global Chemotherapy Induced Nausea & Vomiting (CINV) Market: Size, Trends & Forecasts (2016-2020) - Key Players are Merck, Novartis & Heron Therapeutics - Research and Markets

Research and Markets has announced the addition of the "Global Chemotherapy Induced Nausea & Vomiting (CINV) Market" report to their offering.

Technical Roundup on Drug Makers Stocks -- Tonix Pharma, Retrophin, Heron Therapeutics, and GW Pharma

Stock-Callers.com is currently assessing the most recent performances of the following major players in the Drug Manufacturers segment: Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP), Retrophin Inc....

Heron Therapeutics Announces Presentations of Results from Phase 2 Clinical Trial of HTX-011 in Hernia Repair at PAINWeek(R) 2016

--Substantial decrease in overall opioid use and in the proportion of patients requiring opioids through 96 hours post-surgery

Heron Therapeutics Announces Poster Presentations of Data from Phase 2 Clinical Program for HTX-011 at PAINWeek(R) 2016

Heron Therapeutics, Inc. (NASDAQ: HRTX), a biotechnology company focused on improving the lives of patients by developing best-in-class medicines that address major unmet medical needs, today...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting....

See More

Support & Resistance

2nd Resistance Point 13.40
1st Resistance Point 13.10
Last Price 12.80
1st Support Level 12.50
2nd Support Level 12.20

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.